Get the Stockscreener App
15.98
1.23%
0.195
Arcutis Biotherapeutics Inc stock is traded at $15.98, with a volume of 1.41M.
It is up +1.23% in the last 24 hours and up +9.86% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.79
Open:
$15.5
24h Volume:
1.41M
Relative Volume:
0.79
Market Cap:
$1.92B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-4.0778
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-5.36%
1M Performance:
+9.86%
6M Performance:
+22.77%
1Y Performance:
+92.13%
1-Day Range:
$15.43
$16.27
1-Week Range:
$15.43
$17.29
52-Week Range:
$8.03
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
15.98 | 2.01B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics Inc. Recovers — But Is It Sustainable2025 Pullback Review & AI Based Buy/Sell Signal Reports - thegnnews.com
Arcutis to Present at Upcoming Investor Conferences - MarketScreener
Immuno-Dermatology Leader Arcutis Lines Up Triple Conference Presence: Citi, Morgan Stanley & HC Wainwright - Stock Titan
AI Tools Suggest Arcutis Biotherapeutics Inc. May Outperform This WeekJuly 2025 Big Picture & Risk Adjusted Buy and Sell Alerts - beatles.ru
Published on: 2025-08-18 05:53:18 - Newser
Will Arcutis Biotherapeutics Inc. bounce back from current supportJobs Report & Growth Oriented Trading Recommendations - Newser
What technical models suggest about Arcutis Biotherapeutics Inc.’s comeback2025 Breakouts & Breakdowns & Safe Entry Zone Tips - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysisBull Run & Accurate Trade Setup Notifications - Newser
Analyzing recovery setups for Arcutis Biotherapeutics Inc. investorsJuly 2025 Trade Ideas & Safe Entry Point Alerts - Newser
Is Arcutis Biotherapeutics Inc. a defensive stockEarnings Overview Summary & Real-Time Stock Entry Alerts - thegnnews.com
Is Arcutis Biotherapeutics Inc. still worth holding after the dipJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Is Arcutis Biotherapeutics Inc. trending in predictive chart modelsJuly 2025 Reactions & AI Powered Market Entry Ideas - Newser
What recovery options are there for Arcutis Biotherapeutics Inc.Layoff News & Community Verified Watchlist Alerts - Newser
Forecasting Arcutis Biotherapeutics Inc. price range with options data2025 Market Sentiment & Breakout Confirmation Trade Signals - Newser
Published on: 2025-08-16 20:04:51 - Newser
Identifying reversal signals in Arcutis Biotherapeutics Inc.July 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Will Arcutis Biotherapeutics Inc. price bounce be sustainableMarket Risk Summary & Fast Gain Swing Alerts - Newser
Smart tools for monitoring Arcutis Biotherapeutics Inc.’s price actionWeekly Trade Recap & Accurate Trade Setup Notifications - Newser
Why is Arcutis Biotherapeutics Inc. stock going upQuarterly Growth Report & Weekly Momentum Picks - thegnnews.com
Arcutis Biotherapeutics Inc. Stages Intraday Comeback — Trend Change2025 Market WrapUp & Capital Efficient Trading Techniques - 선데이타임즈
Combining machine learning predictions for Arcutis Biotherapeutics Inc.2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
What makes Arcutis Biotherapeutics Inc. stock price move sharplyJuly 2025 Earnings & Reliable Volume Spike Alerts - Newser
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know - MSN
ARQT’s Stock Journey: What Investors Need to Know About Arcutis Biotherapeutics Inc’s Performance - investchronicle.com
How Arcutis Biotherapeutics Inc. stock performs during market volatilityTrade Exit Report & Free AI Powered Buy and Sell Recommendations - Newser
Arcutis Biotherapeutics Inc. stock chart pattern explainedBond Market & Verified Momentum Stock Watchlist - Newser
Analyzing net buyer seller activity in Arcutis Biotherapeutics Inc.Recession Risk & Verified High Yield Trade Plans - Newser
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
Why Arcutis Biotherapeutics Inc. stock attracts strong analyst attentionBear Alert & Momentum Based Trading Ideas - Newser
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Arcutis Biotherapeutics' Burnett Patrick Sells 3847 Shares at $14.03 per Share - AInvest
Burnett, Arcutis Biotherapeutics EVP, sells $53,988 in ARQT stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 - MarketScreener
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $22.00 - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Buy at Wall Street Zen - Defense World
Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 - MSN
Arcutis Biotherapeutics Awards Restricted Stock Units to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Weigh In on GoodRx Holdings (GDRX) and Arcutis Biotherapeutics (ARQT) - AInvest
Arcutis Biotherapeutics Receives Buy Rating and $21.00 Price Target from Morgan Stanley - AInvest
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates - MSN
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $21 to $25 - 富途牛牛
Seborrhoeic Dermatitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma - Barchart.com
Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts - Investing.com
Arcutis' Path to Profitability and Market Leadership in Dermatology - AInvest
Arcutis Biotherapeutics: Scaling ZORYVE Foam to Redefine Psoriasis Treatment and Drive Sustainable Growth - AInvest
Transcript : Arcutis Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth - TipRanks
Arcutis (ARQT) Q2 Revenue Soars 164% - The Globe and Mail
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating - TipRanks
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcutis Biotherapeutics Inc Stock (ARQT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Aug 08 '25 |
Sale |
14.03 |
3,847 |
53,988 |
108,999 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):